Inform
patients that EPI can be a chronic condition and may require long-term management.2,3
Follow-up appointments are an important way to assess if your patients are receiving an appropriate dose and taking their CREON correctly. During follow-ups, continue to discuss and evaluate any changes in weight, administration habits, and/or symptoms to determine if your patient’s dose is appropriate and whether a dose adjustment is necessary.
Encourage patients to use the Treatment Tracker to record their symptoms, dietary habits, and dosing/administration routines and share it with you at their next follow-up appointment.
Clinical symptoms
Degree of steatorrhea present
Dietary fat content
*In clinical studies, improvement in fat absorption after treatment with CREON was assessed as early as 5-7 days.
†The CFF Guidelines also provide a dietary fat-based maximum lipase dose of less than 4,000 units per g of fat ingested per day.
EPI = exocrine pancreatic insufficiency.
CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.
Please see Full Prescribing Information.
US-CREO-220154
References: 1. CREON [package insert]. North Chicago, IL: AbbVie Inc. 2. Capurso G, Traini M, Piciucchi M, Signoretti M, Arcidiacono PG. Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. Clin Exp Gastroenterol. 2019;12:129-139. doi:10.2147/CEG.S168266 3. Singh VK, Haupt ME, Geller DE, Hall JA, Quintana Diez PM. Less common etiologies of exocrine pancreatic insufficiency. World J Gastroenterol. 2017;23(39):7059-7076.